MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.

Panda, Mamta; Kalita, Elora; Singh, Satyendra; Kumar, Ketan; Rao, Abhishek; Prajapati, Vijay Kumar

Panda, Mamta; Kalita, Elora; Singh, Satyendra; Kumar, Ketan; Rao, Abhishek; Prajapati, Vijay Kumar.

Afiliación

Panda M; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Kalita E; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Singh S; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Kumar K; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Rao A; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Prajapati VK; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India. Electronic address: vkprajapati@curaj.ac.in.

Life Sci ; 305: 120761, 2022 Sep 15.

Article en En | MEDLINE | ID: mdl-35787998

Asunto(s)

COVID-19; MicroARNs; Humanos; MicroARNs/genética; MicroARNs/metabolismo; SARS-CoV-2

Palabras clave

Biomarker; MiRNA; Pathogen-host interaction; RNA silencing; SARS coronavirus 2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs / COVID-19 Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Life Sci Año: 2022 Tipo del documento: Article País de afiliación: India Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google